Boehringer on medicine council: The devil is in the detail
At German firm Boehringer Ingelheim, the head of marketing and sales is ready to discuss both risk sharing and new fixed priced models in health systems within a pressured Europe, which also extends to Denmark where a medicine council is in the works. However the executive stresses that there must be fair payment for innovation.
BY STEFAN SINGH KAILAY
INGELHEIM
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s prize asset shows potential in Alzheimer’s
For abonnenter
